Fundraising FoxCelexorbio
Oakland, US · 1 known investors
Find your way into Celexorbio
Sign up to find every way you can get introduced to Celexorbio
- Your email: who you already know at Celexorbio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Celexorbio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Celexor Bio develops monoclonal antibody therapeutics targeting plasmacytoid dendritic cells to treat severe autoimmune and inflammatory disorders by interrupting the inflammatory cascade at its source. The company's lead candidate, CLXR-901, is designed to deplete pathological pDCs and modify disease progression in underserved patient populations.
Investors · 1
Related companies · 5
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Lexicon PharmaceuticalsLexicon Pharmaceuticals develops and commercializes pharmaceutical products, including the marketed drug INPEFA and drug candidates in clinical development such as sotagliflozin, pilavapadin, and LX9851, serving patients in need of treatments across various therapeutic areas.
Celldex Therapeutics, Inc.Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.
LexeotxLexeo is a clinical-stage genetic medicine company developing gene therapies that target the genetic causes of cardiovascular diseases. Based in New York City, it focuses on treatments for heart health and other genetic diseases regardless of prevalence.
Scilex HoldingScilex Holding Company (Nasdaq: SCLX) acquires, develops, and commercializes non-opioid pain management products for treating acute and chronic pain. It operates in the pharmaceutical industry, offering topical delivery systems and oral analgesic formulations.
Companies working in the same space as Celexorbio.
Frequently asked questions
- What does Celexorbio do?
- Celexor Bio develops monoclonal antibody therapeutics targeting plasmacytoid dendritic cells to treat severe autoimmune and inflammatory disorders by interrupting the inflammatory cascade at its source. The company's lead candidate, CLXR-901, is designed to deplete pathological pDCs and modify disease progression in underserved patient populations.
- Who are Celexorbio's investors?
- Celexorbio's investors include Aditum Bio.
- Where is Celexorbio headquartered?
- Celexorbio is headquartered in Oakland, US.